RESEARCH MONOGRAPH · KDC-MN-212

Vilazodone

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

69/100

Forest Labs' SSRI plus 5-HT1A partial agonist gambit. Differentiation real, market success not so much

Vilazodone is one of those drugs that has more pharmacological interest than commercial success, and the gap between those two is part of why it remains a useful tool compound even though clinical use is modest. Forest Labs (now AbbVie) developed it as an SSRI plus 5-HT1A partial agonist, the theory being that direct 5-HT1A agonism would bypass the autoreceptor-desensitization delay that contributes to the 2-6 week onset latency of conventional SSRIs. FDA approval came in 2011.

The mechanism story is reasonable. SERT inhibition handles the conventional SSRI action. 5-HT1A partial agonism at somatodendritic and postsynaptic receptors theoretically allows direct serotonin signaling at limbic targets even before the autoreceptors desensitize and the SERT inhibition has fully boosted synaptic 5-HT. The pharmacology is similar in concept to vortioxetine's 5-HT1A piece but with cleaner receptor selectivity (vilazodone hits less of the broader serotonin receptor family).

Whether the dual mechanism actually accelerated onset in human trials is genuinely contested. Some endpoints in the registration trials showed faster response than expected, others didnt separate from conventional SSRIs at the same time points. The meta-analytic picture across MDD trials puts vilazodone roughly in the middle of the antidepressant class for efficacy, with acceptability somewhat limited by GI tolerability (nausea is the dominant adverse effect, worse than most SSRIs in the first weeks).

What's interesting from a research perspective: vilazodone is the cleanest pharmacological combination of SERT inhibition and 5-HT1A partial agonism in clinical use, which makes it a useful tool compound for studying that receptor combination separately from the more promiscuous serotonergic activity of vortioxetine. The 5-HT1A partial agonism is well-characterized and the off-target receptor profile is comparatively clean.

What we don't like: nausea / GI tolerability is meaningfully worse than the cleaner SSRIs, and the requirement to take it with food (otherwise oral bioavailability drops dramatically) is an inconvenience clinicians underemphasize. Cost was a barrier during the patent years, but generic vilazodone HCl has been available in the US since 2022 and pricing has normalized.

Sourcing is straightforward post-generic, reference standards are available though less commonly stocked than for the bigger SSRIs. For dual SERT / 5-HT1A pharmacology research its a useful and underused tool. Clinically not first-line for most prescribers, but pharmacologically more interesting than the market share suggests.

Evidence: 72
Mechanism: 82
Reliability: 65
Safety: 75
Sourcing: 75
Value: 65
Signal: 55
Staying power: 60

Plain-language summary Intrigue 53 / 100

Vilazodone (Viibryd) is an antidepressant from Forest Pharmaceuticals, approved in 2011, designed to do two things at once: block the serotonin pump like an SSRI and also directly partially activate the 5-HT1A serotonin receptor. The theory was that hitting 5-HT1A directly would short-circuit the slow autoreceptor desensitization process that normally delays SSRI response by several weeks. In practice the speed advantage in trials has been modest, and the drug has not displaced standard SSRIs as a first-line option. It does have somewhat lower rates of sexual dysfunction than SSRIs, which is its main practical selling point. Must be taken with food (at least 500 calories) for adequate absorption. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

SSRI + 5-HT1A partial agonist

A dual-mechanism antidepressant combining SSRI activity with 5-HT1A partial agonism intended to accelerate clinical response.

Abstract

Vilazodone (5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide; CAS 163521-12-8; molecular formula C26H27N5O2; molecular weight 441.53) is an SSRI plus 5-HT1A partial agonist developed at Merck KGaA and Forest Pharmaceuticals, approved by the FDA in 2011 under the trade name Viibryd. SERT affinity is approximately 0.1 nM; 5-HT1A affinity is approximately 0.2 nM (intrinsic activity approximately 70 percent), producing partial agonism at the autoreceptor. The dual mechanism was designed to bypass the autoreceptor desensitization period that delays SSRI response: by directly activating 5-HT1A receptors while blocking SERT, vilazodone aims to produce faster clinical effect. Real-world clinical trials have shown modest response acceleration. Plasma half-life is approximately 25 hours; metabolism is via CYP3A4 (primary). Approved for major depressive disorder. The compound is administered with food, which doubles bioavailability compared to fasted dosing. Used as a reference compound for 5-HT1A partial agonist plus SSRI pharmacology.

Mechanism of action

Combined SERT inhibition and 5-HT1A partial agonism. Designed to accelerate clinical response by bypassing autoreceptor desensitization.

Reported research dose ranges

Reported research dose ranges in the literature.

References

Khan A, Macaluso M, et al. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Expert Opin Investig Drugs 2012.
Heinrich T, et al. Synthesis and structure-activity relationships in a class of serotonergic N-acylated amine ligands. J Med Chem 2004.
Reinhold JA, Mandos LA, Rickels K, Lohoff FW. Pharmacological treatment of generalized anxiety disorder. Expert Opin Pharmacother 2011.

Read the full monograph

Available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-212

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Vilazodone

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs